Evidence map›Paper›PMID 29656309›Full record

ArticleEuropean journal of clinical pharmacology2018

Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey.

Florence Moulis, Vanessa Rousseau, Leila Chebane, Amandine Gouverneur, Louise Gaboriau, Jean-Luc Faillie, Geneviève Durrieu, François Montastruc, Jean-Louis Montastruc

Abstract readLetter
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Florence MoulisService de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC 1436, INSERM UMR 1027, Faculté de Médecine, Centre Hospitalier Universitaire, 37, allées Jules-Guesde, 31000, Toulouse, France.
Vanessa RousseauService de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC 1436, INSERM UMR 1027, Faculté de Médecine, Centre Hospitalier Universitaire, 37, allées Jules-Guesde, 31000, Toulouse, France.
Leila ChebaneService de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC 1436, INSERM UMR 1027, Faculté de Médecine, Centre Hospitalier Universitaire, 37, allées Jules-Guesde, 31000, Toulouse, France.
Amandine GouverneurService de Pharmacologie Médicale, Centre de PharmacoVigilance, Centre Hospitalier Universitaire, Pôle de Santé Publique, Inserm Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, University of Bordeaux, 33000, Bordeaux, France.
Louise GaboriauCentre de PharmacoVigilance du Nord Pas-de-Calais, CHRU, 1 place de Verdun, 59037, Lille cedex, France.
Jean-Luc FaillieCentre Régional de PharmacoVigilance, CHU Montpellier, 34295, Montpellier, France.
Geneviève DurrieuService de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC 1436, INSERM UMR 1027, Faculté de Médecine, Centre Hospitalier Universitaire, 37, allées Jules-Guesde, 31000, Toulouse, France.
François MontastrucService de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC 1436, INSERM UMR 1027, Faculté de Médecine, Centre Hospitalier Universitaire, 37, allées Jules-Guesde, 31000, Toulouse, France.
Jean-Louis MontastrucService de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC 1436, INSERM UMR 1027, Faculté de Médecine, Centre Hospitalier Universitaire, 37, allées Jules-Guesde, 31000, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PharmacovigilanceAdultAdverse Drug Reaction Reporting SystemsAgedAged, 80 and overAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsFemaleFranceHumansMaleMiddle AgedRetrospective StudiesTetrazolesAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Identifiers

PMID29656309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.